Home › Ovarian Cancer › California
Ovarian Cancer clinical trials in California
104 studies for Ovarian Cancer are looking for participants at sites in California.
Cities in California
- Los Angeles49 studies
- Baldwin Park25 studies
- San Diego24 studies
- Mountain View19 studies
- San Francisco18 studies
- Orange16 studies
- Santa Monica15 studies
- Irvine12 studies
- Newport Beach9 studies
- Sacramento7 studies
- Fullerton6 studies
- Santa Rosa6 studies
- Santa Barbara5 studies
- Pleasanton4 studies
- San Jose4 studies
- Vallejo4 studies
- Fresno4 studies
- Burbank4 studies
- Concord4 studies
- Richmond3 studies
- Oakland3 studies
- Fremont3 studies
- Modesto3 studies
- Torrance3 studies
- Long Beach3 studies
- Elk Grove3 studies
- Antioch3 studies
- Redwood City3 studies
- Arden-Arcade3 studies
- Roseville3 studies
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
- City of Hope National Medical Center /ID# 281381, Duarte
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 280914, Irvine
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07278336A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Duarte
- Research Site, Los Angeles
- Research Site, Newport Beach
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05877599Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- PCR Oncology, Arroyo Grande
- Mercy Cancer Center - Carmichael, Carmichael
- Mercy San Juan Medical Center, Carmichael
- and 15 more
RecruitingPhase 2
All ages · All sexes · Updated Sep 29, 2026 · NCT05564377A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- UCLA - University of California Los Angeles Medical Center /ID# 274566, Los Angeles
- Scripps Md Anderson - Prebys Cancer Center /ID# 276891, San Diego
- California Pacific Medical Center - Van Ness Campus /ID# 275329, San Francisco
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT06890338A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- University of California - Los Angeles, Los Angeles
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Sep 28, 2026 · NCT06586957DESTINY-PANTUMOUR04
- Research Site, San Diego
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- University of California San Diego, La Jolla
- Stanford University, Palo Alto
- UCLA Medical Center, Santa Monica
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- City of Hope, Duarte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06172478A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- City of Hope Comprehensive Cancer Center, Duarte
- The City of Hope Orange County Lennar Foundation Cancer Center, Irvine
- Chao Family Comprehensive Cancer Center, Orange
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT04590326A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- Kivu Trial Site, Santa Monica
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07229313Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Los Angeles
- Research Site, Santa Rosa
RecruitingPhase 2
Ages 18 to 130 · All sexes · Updated Sep 23, 2026 · NCT05489211Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- UC IRVINE Health, Orange
- UC Davis Comprehensive Cancer Center, Sacramento
- Stanford Cancer Institute, Stanford
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- UC San Diego Health - Moores Cancer Center /ID# 277574, La Jolla
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 22, 2026 · NCT07059845A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Hoag Memorial Hospital Presbyterian, Newport Beach
- Stanford University Medical Center, Stanford
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213791A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center, Burbank
- City of Hope, Duarte, Duarte
- City of Hope Lennar, Irvine
- and 6 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213804Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Beverly Hills Cancer Center, Beverly Hills
- City of Hope Cancer Center, Duarte
- University of California Irvine Medical Center, Orange
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
- City of Hope National Medical Center, Duarte
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT04752826A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- City of Hope, Duarte
- City of Hope, Irvine, Irvine
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07109726A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- John Muir Health Cancer Center ( Site 0069), Walnut Creek
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT07318558Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- City of Hope Medical Center, Duarte
- Providence Medical Foundation, Fullerton
- University of California, San Diego-Moores Cancer Center, La Jolla
- and 3 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 15, 2026 · NCT07214779The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of San Diego Moores Cancer Center, La Jolla
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- University of California, Los Angeles Medical Center, Los Angeles
- Scripps Healthscripps Mercy Hospital Prebys Cancer Center, San Diego
RecruitingPhase 2
Ages 18 to 99 · Women · Updated Sep 15, 2026 · NCT07023627ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of California, San Diego, La Jolla
- Hoag Memorial Hospital Presbyterian, Newport Beach
- Redwood City, Redwood City
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- UC San Diego Health, La Jolla
- Cedars Sinai Medical Center, Los Angeles
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 14, 2026 · NCT06787612A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Santa Monica
- Research Site, Santa Rosa
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT05123482Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- City of Hope, Duarte
- START - Los Angeles, Los Angeles
- Cedars Sinai, Los Angeles
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors
- Stanford University, Palo Alto
RecruitingPhase 1
Ages 18 and older · Women · Updated Sep 10, 2026 · NCT06646627A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06400472A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- City of Hope National Medical Center, Duarte
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06465069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- City of Hope - Duarte Cancer Center, Duarte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06760819A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- UCSF Medical Center at Mission Bay ( Site 0013), San Francisco
- John Muir Health Cancer Center ( Site 0016), Walnut Creek
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06824467FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- UC San Diego Moores Cancer Center, La Jolla
- University of Southern California, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07216105The Vanguard Study: Testing a New Way to Screen for Cancer
- Kaiser Permanente-Division of Research, Pleasanton
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Sep 2, 2026 · NCT06995898Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
- Start Cal, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 1, 2026 · NCT07736937Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- University of Southern California, Los Angeles
- Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer, Los Angeles
- Cedars-Sanai Medical Center, Los Angeles
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT06582017Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- City of Hope, Duarte
- UC San Diego Health - Moores Cancer Center, La Jolla
- Hoag Gynecologic Oncology, Newport Beach
- and 1 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Aug 26, 2026 · NCT05281471PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT04329494Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- City of Hope, Duarte
- Stanford, Palo Alto
- University of California, San Francisco
RecruitingPhase 1
Ages 15 and older · All sexes · Updated Aug 25, 2026 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital Los Angeles, Los Angeles
- Children's Hospital of Orange County, Orange
- UCSF Medical Center-Mission Bay, San Francisco
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Hoag Family Cancer Institute, Newport Beach
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06774963From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.